Thus, the current study supports the competent cytotoxic effect of CDRI-08 against androgen-independent prostate cancer cell lines, PC3, targeting the PI3K/Akt pathway, in combination with CYP17A1 inhibitor, AA, even in the presence of EGF and DHT. The gene discussed is AKT1; the disease is prostate carcinoma.